2'-cyano-2'-deoxyarabinofuranosylcytosine has been researched along with cytarabine in 29 studies
| Studies (2'-cyano-2'-deoxyarabinofuranosylcytosine) | Trials (2'-cyano-2'-deoxyarabinofuranosylcytosine) | Recent Studies (post-2010) (2'-cyano-2'-deoxyarabinofuranosylcytosine) | Studies (cytarabine) | Trials (cytarabine) | Recent Studies (post-2010) (cytarabine) |
|---|---|---|---|---|---|
| 31 | 0 | 6 | 15,487 | 2,424 | 3,188 |
| Protein | Taxonomy | 2'-cyano-2'-deoxyarabinofuranosylcytosine (IC50) | cytarabine (IC50) |
|---|---|---|---|
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 7.533 | |
| E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | 0.02 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (41.38) | 18.2507 |
| 2000's | 10 (34.48) | 29.6817 |
| 2010's | 6 (20.69) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Azuma, A; Hanaoka, K; Kobayashi, T; Matsuda, A; Minakawa, N; Nakajima, Y; Nishizono, N; Sasaki, T; Suzuki, M; Tanaka, M | 1 |
| Matsuda, A; Sasaki, T; Tanaka, M; Terao, T | 1 |
| Azuma, A; Matsuda, A; Nakajima, Y; Sasaki, T; Tanaka, M | 1 |
| Azuma, A; Matsuda, A; Nakajima, Y; Sasaki, T; Ueda, T | 1 |
| Azuma, A; Hanaoka, K; Kamo, N; Kobayashi, T; Kurihara, A; Matsuda, A; Miyauchi, S; Sasaki, T; Tanaka, M | 1 |
| Matsuda, A | 2 |
| Endo, Y; Matsuda, A; Obata, T; Sasaki, T; Tanaka, M | 1 |
| Matsuda, A; Sasaki, T | 1 |
| Hayakawa, Y; Kataoka, M; Kawai, R; Matsuda, A; Otsuki, K | 1 |
| Endo, Y; Sasaki, T; Zhang, M | 1 |
| Hanaoka, K; Hisaoka, M; Ikeda, T; Iwabuchi, H; Kaneko, M; Kobayashi, T; Kurakata, S; Matsuda, A; Mitsuhashi, Y; Miura, S; Nakagawa, A; Nomura, T; Sasaki, T; Shibayama, T; Suzuki, M; Tanaka, K; Tanzawa, F; Tomida, A; Tsuruo, T; Wataya, Y | 1 |
| Asai, T; Kakiuchi, T; Matsuda, A; Ohba, H; Oku, N; Shuto, S; Tsukada, H | 1 |
| Azuma, A; Huang, P; Matsuda, A; Plunkett, W | 2 |
| Kodama, T; Matsuda, A; Nomura, M; Shuto, S | 1 |
| Endo, Y; Matsuda, A; Obata, T; Sasaki, T; Tanaka, M; Uchida, H | 1 |
| Asai, T; Kondo, M; Kuromi, K; Matsuda, A; Ogino, K; Oku, N; Shimizu, K; Shuto, S; Taki, T; Watanabe, K | 1 |
| Azuma, A; Chubb, S; Guo, Y; Hittelman, W; Huang, P; Jiang, Y; Li, Y; Liu, X; Matsuda, A; Plunkett, W | 1 |
| Benhadji, K; Calvo, F; Chiao, J; Cvitkovic, E; Faivre, S; Galmarini, CM; Ghoul, A; Green, SR; Le Tourneau, C; Raymond, E; Serova, M | 1 |
| Liu, X; Matsuda, A; Plunkett, W | 1 |
| Liu, X; Matsuda, A; Plunkett, W; Wang, Y | 1 |
| Benaissa, S; Estrov, Z; Kantarjian, H; Liu, X; Matsuda, A; Plunkett, W; Wang, Y | 1 |
| Liu, XJ; Nowak, B; Plunkett, W; Wang, YQ | 1 |
| Hargis, S; Jiang, Y; Liu, X; Nowak, B; Plunkett, W | 1 |
| Al Abo, M; Huang, SY; Kiselev, E; Liu, X; Plunkett, W; Pommier, Y; Rajapakse, VN; Sasanuma, H; Takeda, S | 1 |
| Chen, Y; Cheng, N; Jiang, Y; Liu, X; Nowak, B; Plunkett, W; Qiang, B | 1 |
| Eshima, K; Fukushima, M; Iizuka, K; Jin, C; Zhang, C | 1 |
| Ichikawa, S; Jiang, Y; Liu, X; Matsuda, A; Nowak, B; Ohtawa, M; Plunkett, W | 1 |
2 review(s) available for 2'-cyano-2'-deoxyarabinofuranosylcytosine and cytarabine
| Article | Year |
|---|---|
[Nucleoside kinases and new types of antitumor nucleosides].
Topics: Antimetabolites, Antineoplastic; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Nucleic Acid Synthesis Inhibitors; Phosphotransferases | 1997 |
[Why is the DNA-strand-breaker, PCNDAC, effective to solid tumors?].
Topics: Animals; Apoptosis; Cytarabine; DNA Damage; DNA, Neoplasm; Drug Design; Gene Deletion; Genes, p53; Humans; Mice; Mice, Nude; Necrosis; Neoplasms; Point Mutation; Prodrugs; RNA, Neoplasm | 1998 |
27 other study(ies) available for 2'-cyano-2'-deoxyarabinofuranosylcytosine and cytarabine
| Article | Year |
|---|---|
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
Topics: Adenine; Animals; Antineoplastic Agents; Cytarabine; Female; Fluorouracil; Humans; Leukemia L1210; Lymphoma, Large B-Cell, Diffuse; Mice; Molecular Structure; Neoplasm Transplantation; Structure-Activity Relationship; Thymine; Tumor Cells, Cultured; Uracil | 1993 |
Antitumor activity of a novel nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine (CNDAC) against murine and human tumors.
Topics: Animals; Antineoplastic Agents; Cell Survival; Chick Embryo; Cytarabine; Cytidine Deaminase; Humans; Leukemia P388; Mice; Mice, Nude; Tumor Cells, Cultured | 1992 |
Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.
Topics: Animals; Antineoplastic Agents; Cytarabine; DNA; Drug Design; Drug Screening Assays, Antitumor; Leukemia P388; Mice; Tumor Cells, Cultured | 1991 |
Synthesis of a new potent antitumor nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D- arabinofuranosylcytosine.
Topics: Antineoplastic Agents; Cytarabine; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Tumor Cells, Cultured | 1990 |
Nucleosides and nucleotides. 141. Chemical stability of a new antitumor nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine in alkaline medium: formation of 2'-C-cyano-2'-deoxy-1-beta-D-ribo-pentofuranosylcytosine and its antitumor act
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Colonic Neoplasms; Cytarabine; Drug Stability; Female; Humans; Hydrogen-Ion Concentration; Leukemia P388; Mice; Mice, Inbred DBA; Ribonucleosides; Spectrum Analysis; Tumor Cells, Cultured | 1995 |
[Design of a new antitumor nucleoside CNDAC, against solid tumors].
Topics: Antineoplastic Agents; Cytarabine; DNA Damage; DNA Polymerase II; DNA, Neoplasm; Drug Design; Drug Screening Assays, Antitumor; Humans; Neoplasms | 1996 |
Development and biochemical characterization of a 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC)-resistant variant of the human fibrosarcoma cell line HT-1080.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Deoxycytidine Kinase; DNA, Neoplasm; Drug Resistance, Neoplasm; Fibrosarcoma; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genes; Humans; RNA, Neoplasm; Tumor Cells, Cultured | 1998 |
Evidence supporting the activity of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentafuranosylcytosine as a terminator in enzymatic DNA-chain elongation.
Topics: Antineoplastic Agents; Cytarabine; DNA; Hydrogen-Ion Concentration; Magnetic Resonance Spectroscopy; Models, Chemical; Nucleic Acid Conformation | 1998 |
Determinants in chemosensitivity of oncogene-transformed NIH3T3 cells to 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Cell Division; Cell Transformation, Neoplastic; Chick Embryo; Cytarabine; Cytidine Deaminase; Deoxycytidine Kinase; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oncogenes; Transformation, Genetic; Tritium | 1999 |
Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Biotransformation; Breast Neoplasms; Cisplatin; Cytarabine; Cytosine; Deoxycytidine; Deoxycytidine Kinase; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; KB Cells; Leukemia P388; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Mitomycin; Molecular Structure; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Rats; Rats, Nude; Specific Pathogen-Free Organisms; Stomach Neoplasms; Tumor Cells, Cultured; Vincristine | 1999 |
Targeting and anti-tumor efficacy of liposomal 5'-O-dipalmitoylphosphatidyl 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine in mice lung bearing B16BL6 melanoma.
Topics: Animals; Antineoplastic Agents; Cytarabine; Liposomes; Lung Neoplasms; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Tomography, Emission-Computed | 2001 |
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.
Topics: Antineoplastic Agents; CDC2 Protein Kinase; Chromosome Breakage; Cyclin B; Cyclin B1; Cytarabine; Deoxycytidine; DNA, Neoplasm; G2 Phase; Gemcitabine; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Phosphorylation; RNA; Tumor Cells, Cultured | 2001 |
Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC).
Topics: Antineoplastic Agents; Cell Division; Cytarabine; Deoxycytosine Nucleotides; Deoxyribonucleotides; DNA; Humans; RNA; Tumor Cells, Cultured | 2001 |
An efficient method for the preparation of 1'alpha-branched-chain sugar pyrimidine ribonucleosides from uridine: the first conversion of a natural nucleoside into 1'-substituted ribonucleosides.
Topics: Cyclization; Cytarabine; Cytidine; Deoxycytidine; Glycosylation; Molecular Structure; Organoselenium Compounds; Pyrimidine Nucleosides; Ribonucleosides; Selenium; Silicon; Stereoisomerism; Structure-Activity Relationship; Uridine; Vinyl Compounds | 2001 |
Deletion mutants of human deoxycytidine kinase mRNA in cells resistant to antitumor cytosine nucleosides.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Fibrosarcoma; Gene Deletion; Gene Expression; Humans; Inhibitory Concentration 50; Melanoma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2001 |
Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels.
Topics: Amino Acid Sequence; Angiogenesis Inhibitors; Animals; Cytarabine; Drug Delivery Systems; Liposomes; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Oligopeptides; Phosphatidic Acids; Survival Analysis; Time Factors; Tissue Distribution; Treatment Outcome; Tumor Cells, Cultured | 2002 |
Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
Topics: Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Line, Tumor; Checkpoint Kinase 1; Chromosome Aberrations; Cytarabine; DNA Damage; Drug Interactions; G2 Phase; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Mitosis; Protein Kinases; Signal Transduction; Staurosporine | 2005 |
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Topics: 5'-Nucleotidase; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cytarabine; Cytosine; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Taxoids | 2007 |
Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine.
Topics: Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cytarabine; DNA Damage; DNA-Activated Protein Kinase; G2 Phase; Humans; Protein Serine-Threonine Kinases | 2008 |
Repair of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine-induced DNA single-strand breaks by transcription-coupled nucleotide excision repair.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; Cytarabine; Cytosine; Dioxolanes; DNA Damage; DNA Repair; HeLa Cells; Humans; Mice; Transcription, Genetic; Tumor Suppressor Protein p53 | 2008 |
Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Cell Line; Cell Line, Tumor; Cell Survival; CHO Cells; Cricetinae; Cricetulus; Cytarabine; DNA Breaks, Double-Stranded; DNA Replication; DNA, Single-Stranded; Drug Resistance; Female; HCT116 Cells; HeLa Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombination, Genetic; Sister Chromatid Exchange; Young Adult | 2010 |
Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
Topics: Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; CHO Cells; Cricetinae; Cricetulus; Cytarabine; Cytosine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Gemcitabine; Homologous Recombination; Inhibitory Concentration 50; Prodrugs | 2012 |
Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cricetinae; Cytarabine; Dacarbazine; DNA Breaks; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Homologous Recombination; Humans; Platinum; Poly (ADP-Ribose) Polymerase-1; Temozolomide; Tumor Suppressor Protein p53 | 2016 |
TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors.
Topics: Arabinonucleosides; BRCA2 Protein; Camptothecin; Colorectal Neoplasms; Cytarabine; Cytosine; DNA Breaks, Single-Stranded; DNA Damage; DNA Repair; DNA Replication; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Phosphoric Diester Hydrolases; Poly (ADP-Ribose) Polymerase-1 | 2017 |
Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; Chromosome Aberrations; Cytarabine; DNA Damage; Drug Synergism; Female; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Poly (ADP-Ribose) Polymerase-1; Tumor Stem Cell Assay | 2018 |
Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Infusions, Intravenous; Isoflurophate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays | 2018 |
Repair of DNA damage induced by the novel nucleoside analogue CNDAG through homologous recombination.
Topics: Cell Survival; Cytarabine; DNA Damage; DNA Repair; Homologous Recombination; Humans; Leukemia, T-Cell; Phosphorylation; Tumor Cells, Cultured | 2020 |